Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data* by Fox, K M et al.
Effectiveness of statins in Medicare-eligible patients
and patients < 65 years using clinical practice data*
K. M. Fox,
1 S. K. Gandhi,
2 R. L. Ohsfeldt,
3 J. W. Blasetto,
4 M. H. Davidson
5
Introduction
Management of patients with hyperlipidaemia
remains an important healthcare issue as coronary
heart disease (CHD) continues to be the leading
cause of mortality and morbidity in the United States
(US) affecting 13 million Americans and costing
$130 billion annually (1). The National Cholesterol
Education Program (NCEP) Adult Treatment Panel
III (ATP III) guidelines highlighted the importance
of aggressive hyperlipidaemia treatment by recom-
mending LDL-C goal < 100 mg/dl for high-risk
patients (2). In July 2004, an optional LDL-C goal
< 70 mg/dl for very high-risk patients was recom-
mended (3).
Investigations of patients treated with statins by
community-based physicians are limited and indicate
that treatment for hyperlipidaemia may be subopti-
mal (4–6) compared with clinical trial efﬁcacy data
(7–11). Reports indicate that many patients are not
managed aggressively to reach ATP III goals, only
38–48% of patients in different health plans achieved
goal (12,13) while only 23–24% of high-risk patients
reached goal (14,15). With this gap in goal attain-
ment, there is a need to determine if one statin is
more effective than others in reducing LDL-C and
attaining LDL-C goal so that physicians may opti-
mise their patient outcomes.
Moreover, with the advent of Medicare D phar-
macy beneﬁts, older patients will potentially have
greater access to statin therapy. Thus, clinicians need
evidence regarding which statin is more effective for
their Medicare-eligible patients (age ‡ 65 years) and
patients < 65 years of age. This study was designed
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SUMMARY
Objective: This study compared effectiveness of rosuvastatin (RSV) with other sta-
tins on lowering LDL-C and LDL-C goal attainment among Medicare-eligible
patients (age ‡ 65 years) and patients with age < 65 years treated in usual clini-
cal practice to provide evidence of real-world effectiveness of statins. Methods:
Retrospective cohort study was conducted in patients, newly prescribed statin ther-
apy during August 2003 to May 2005. Patient inclusion criteria: no prior prescrip-
tion for dyslipidaemic medication in the preceding 12 months, continuously
enrolled for ‡ 15 months and ‡ 90-day supply of statin. Effectiveness of RSV in
reducing LDL-C and attaining LDL-C goal when compared with other statins was
evaluated using multivariate regression, adjusting for baseline LDL-C, age, gender,
smoking, hypertension, coronary heart disease (CHD), systolic blood pressure and
therapy duration. Results: Adjusted per cent LDL-C reduction was signiﬁcantly
greater (p < 0.05) with RSV (24.3% for ‡ 65 and 28.5% for < 65) compared
with ATV (17.5%, 21.3%), SMV (14.8%, 18.4%), PRV (11.3%, 15.8%), FLV
(10.7%, 20.6%) and LOV (13.3%, 14.4%). Among patients in both age groups at
high or moderate CHD risk, a greater proportion of RSV patients attained LDL-C
goal (76.0% for age group ‡ 65 years and 78.4% for age group < 65 years) vs.
50.5–73.0% for ‡ 65 and 51.3–71.5% for < 65 years of age on other statins
(p < 0.0001). Conclusions: Rosuvastatin is more effective in lowering LDL-C in
Medicare-eligible patients and patients < 65 years of age when compared with
other statins in usual clinical practice. Moreover, RSV patients had higher LDL-C
goal attainment rates when compared with other statins in high- and moderate-
risk patients. The study results have implications for clinicians in selecting the
optimal statin to meet individual patient care needs.
What’s known
Clinical trials have shown that statins are
efﬁcacious in managing dyslipidaemia and that
rosuvastatin is more efﬁcacious than other statins
in lowering LDL-C. There have been only a few
studies that examined the effectiveness of statins in
clinical practice, outside the controlled trial setting.
Most of these studies have not included
rosuvastatin as it was introduced to the market
later.
What’s new
This investigation provides estimates of LDL-C
lowering and LDL-C goal attainment among
patients ‡ 65 years of age which has not been a
focal point of other studies. Previous investigations
have largely included patients < 65 years of age
because of the lack of available databases with
lipid results or have not stratiﬁed LDL-C by age
group. Moreover, this study compared all marketed
statins instead of a selected few statins.
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atin (RSV) compared with other statins in reducing
LDL-C and reaching ATP III LDL-C goal among
Medicare-eligible patients and patients < 65 years of
age treated by physicians in usual clinical practice.
This study provides evidence of how effective statins
are in routine clinical practice and whether the effec-
tiveness is similar for younger vs. older patients.
Methods
A retrospective cohort study was conducted utilising
the General Electric Medical System (GEMS) elec-
tronic medical records database of patients treated in
physician practices. The study objective was to exam-
ine the effectiveness of statins under usual care at
reducing LDL-C and ATP III goal attainment by
comparing RSV with atorvastatin (ATV), simvastatin
(SMV), pravastatin (PRV), ﬂuvastatin (FLV) and lov-
astatin (LOV). Older patients, 65 years and older,
were examined separately from patients < 65 years of
age to identify the most effective statin for the Medi-
care and non-Medicare population.
Patients who were newly prescribed statin therapy
during August 2003 to May 2005 and had no prior
prescription for dyslipidaemic medication, including
bile acid sequestrants, ﬁbrin, niacin, ezetimibe or sta-
tin, in the preceding 12 months were included in the
study. The GEMS database included the electronic
medical records (EMR) of patients treated in usual
clinical practice for over 3000 physicians across the
US. The EMR was utilised largely by primary care
physicians (85%) and cardiology practices ( 5%).
All patient care activities (outpatient medical and
procedures, prescriptions, laboratory) in the physi-
cian’s ofﬁce are captured in the EMR.
Titration of statin therapy was allowed but
patients switching to other statins during the study
period were excluded as the effect of the initial statin
could not be isolated in patients switching statins.
Patients had to be continuously enrolled for a mini-
mum of 15 months; 12 months prior to and
3 months after initiation of statin therapy. Addition-
ally, patients were required to have a minimum of
90-day supply of statin therapy (either a 90-day pre-
scription or three 30-day prescriptions), and lipid
results within 90 days prior to and > 30 days after
initiating statin therapy. The lipid value closest to
the date of statin therapy initiation was deﬁned as
the baseline lipid measure. The follow-up lipid value
was deﬁned as the average of all lipid measures dur-
ing the follow-up period, from 30 days after initia-
tion of statin therapy to the date of the last statin
prescription at the time of discontinuation or end of
study (August 2005). The average LDL-C was used
to obtain stable estimates using all available data and
followed the methodology by Bullano et al. (16).
Therapy discontinuation was deﬁned as the lack of a
prescription or reﬁll order within a 50% time period
of the prescription supply. Thus, if a 30-day statin
supply was ordered then the prescription must be
reﬁlled or a new order written within 45 days of the
initial prescription to consider the patient persistent
on statin therapy. Similarly, if a 90-day statin supply
is ordered then the second prescription or reﬁll must
be written within 135 days of the initial prescription
date to consider the patient persistent.
Two effectiveness outcomes were assessed: (1) per
cent reduction in LDL-C and (2) percentage of
patients attaining NCEP ATP III LDL-C goal. The
outcome measures were computed for each individ-
ual statin and then compared with RSV. Change in
total cholesterol, high-density lipoprotein (HDL-C)
and triglycerides was also computed. For LDL-C goal
attainment assessment, patients were stratiﬁed based
upon NCEP CHD risk groups (2). CHD and CHD
risk equivalent was deﬁned as myocardial infarction,
ischaemic heart disease, acute coronary syndrome,
cerebral vascular accident, transient ischaemic attack,
peripheral vascular disease, abdominal aortic aneu-
rysm, angina pectoris, atherosclerosis and diabetes
mellitus based on ICD-9 codes. The GEMS EMR
(outpatient data only) did not contain information
on inpatient procedures so the classiﬁcation of
patients with coronary artery bypass graft, angio-
plasty or other revascularisation into the high-risk
category was not possible. A count of risk factors
was done to assign patients to moderate or low risk.
Moderate-risk patients were deﬁned by the presence
of two or more CHD risk factors including current
cigarette smoking, hypertension diagnosis or blood
pressure ‡ 140/90 mmHg, low HDL-C < 40 mg/dl
and age ‡ 45 for men and ‡ 55 for women. Low-risk
patients were those with one or no CHD risk factors.
Given the lack of inpatient procedures data and
data from non-primary care settings, there was a
potential for misclassifying high-risk patients as
moderate risk. The fact that physicians started these
patients with LDL-C < 130 mg/dl on a statin treat-
ment was considered a strong indicator of their
underlying high-risk status or a more aggressive
LDL-C target goal (< 100 mg/dl). LDL-C goal was
deﬁned as < 100 mg/dl for high-risk patients as well
as those moderate-risk patients who were already at
goal < 130 mg/dl at baseline. Moderate-risk patients
not at LDL-C goal at baseline had a goal of
< 130 mg/dl (2). Low-risk patients’ LDL-C goal was
< 160 mg/dl (2). Moreover, family history of prema-
ture CHD was not available in the EMR and was not
included as one of the risk factors. Thus, some
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of moderate risk.
Linear regression analyses were conducted to com-
pare effectiveness of RSV with other statins in lower-
ing LDL-C while adjusting for age, gender, smoking,
hypertension, CHD, systolic blood pressure, baseline
LDL-C and therapy duration. Logistic regression
analyses were undertaken to compare LDL-C goal
attainment between RSV and other statins while
adjusting for the same baseline characteristics. The
goal attainment analyses were stratiﬁed by CHD risk
level, high plus moderate risk and low risk. The sam-
ple mean of predicted probabilities from the logistic
regression models was used as an estimate of the
expected rate of goal attainment adjusted for patient
characteristics. All statistical analyses were conducted
using SAS version 9.1 (SAS Institute, Inc., Cary,
NC).
Results
There were 5989 patients with age ‡ 65 years, and
5326 patients who were < 65 years of age who met
the study inclusion criteria. RSV patients comprised
4% of the ‡ 65 age group and 6% of the < 65 age
group (Table 1). RSV Medicare-eligible patients (age
‡ 65 years) and patients < 65 years of age had higher
baseline LDL-C (p < 0.05) and total cholesterol
(p < 0.05) than other statin patients except for LOV
(Table 1). RSV patients also had shorter therapy
duration (p < 0.05) than all other statin patients
likely because of relatively recent availability when
compared with other statins. Medicare-eligible RSV
patients were younger than other statin patients
(p < 0.05) except for ATV and SMV (Table 1). For
patients < 65 years of age, RSV patients were signiﬁ-
cantly younger than SMV and LOV patients
(Table 1). For both Medicare-eligible and patients
< 65 years of age, initial statin dose did not vary by
CHD risk level (Table 1).
Lipid changes
Medicare-eligible RSV patients had signiﬁcantly
greater (p < 0.05) LDL-C reduction (29.8%) com-
pared with other statins (11.3–19.1%), despite differ-
ences in age and therapy duration (Table 2). For
patients < 65 years of age, RSV patients had signiﬁ-
cantly greater (p < 0.05) observed LDL-C reduction
(33.6%) compared with other statins (17–23.6%)
(Table 2). After adjustment for differences in baseline
characteristics, both Medicare-eligible patients and
patients < 65 years of age, RSV patients had signiﬁ-
cantly greater LDL-C reduction than other statins
(p < 0.05) (Table 2). After adjustment, patients
< 65 years of age who were treated with RSV had a
28.5% LDL-C reduction compared with 14.4–21.3%
for other statins. Similarly, Medicare-eligible RSV
patients had a greater adjusted (24.3%) per cent
LDL-C reduction compared with other statins (10.7–
17.5%).
Medicare-eligible patients and patients < 65 years
of age treated with RSV had signiﬁcantly greater
reduction in total cholesterol than other statin
patients (Table 3). Medicare-eligible RSV patients
had an adjusted 17.5% reduction in total cholesterol
compared with 7.0–12.2% for other statins, p < 0.05.
Among patients < 65 years of age, RSV had an
adjusted 22.1% total cholesterol reduction compared
with 17.2% for ATV (p ‡ 0.05) and 10.8–14.1% for
other statins (p < 0.05). The average change in
HDL-C for each statin was 0.8–3.4% for Medicare-
eligible and )1.3% to 1.7% for < 65 patients
(Table 3). There was no difference in the change in
triglycerides between RSV and other statins for either
the Medicare-eligible patients or patients < 65 years
of age.
ATP III goal attainment
ATP III goal attainment was computed by CHD
risk level and patients who were at LDL-C goal
level at baseline were excluded. A greater propor-
tion of moderate- and high-risk RSV patients com-
pared with other moderate- and high-risk statin
patients, both Medicare-eligible patients and < 65,
attained ATP III LDL-C goal after adjusting for
baseline differences (Table 4). After adjustment,
approximately 78% of < 65 years of age moderate-
and high-risk patients and 76% of high- and mod-
erate-risk Medicare-eligible patients attained LDL-C
goal on RSV compared with 51–71% of < 65 years
of age patients and 50–73% of older patients tak-
ing other statins (Table 4).
There was little difference across statins in LDL-C
goal attainment among the low-risk patients for both
Medicare-eligible patients and patients < 65 years of
age (Table 4). After adjustment, a signiﬁcantly
greater proportion of low-risk RSV patients
< 65 years of age had attained LDL-C goal compared
with PRV and LOV (p < 0.05). For Medicare-eligible
low-risk patients, a signiﬁcantly greater proportion
of RSV patients attained LDL-C goal than PRV
(p < 0.05) after adjustment for baseline covariates.
Discussion
Rosuvastatin is more effective in lowering LDL-C
in this sample of Medicare-eligible patients and
patients < 65 years of age than other statins. These
greater LDL-C reductions resulted in better goal
attainment among RSV patients, both < 65 and
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patients, 76% attained ATP III LDL-C goals com-
pared with 50–73% of other statin patients. There
was no difference in goal attainment across statins
for low-risk patients. RSV was also more effective
(p < 0.05) in lowering total cholesterol among
Medicare-eligible patients and patients < 65 years
of age than other statins.
Table 1 Baseline characteristics of Medicare-eligible patients and < 65 years of age patients newly initiated on statin therapy
Characteristics Rosuvastatin Atorvastatin Simvastatin Pravastatin Fluvastatin Lovastatin
Medicare-eligible patients (‡ 65 years) (n ¼ 5989)
Number of subjects 235 (4%) 3195 (54%) 1432 (24%) 495 (8%) 256 (4%) 376 (6%)
Age (mean ± SD) 73.3 (5.1) 73.5 (5.0) 74.0 (4.9) 74.1 (5.0)* 74.9 (5.0)* 74.5 (5.0)*
Male (%) 42 44 49 46 42 38
Smoker (%) 7 5 5 4 2 4
Hypertension (%) 55 52 50 53 50 56
CHD (%) 13 14 14 12 12 12
NCEP risk group, n (%)
CHD/CHD risk equivalent 96 (41%) 1557 (49%) 703 (49%) 216 (44%) 124 (48%) 146 (39%)
Mean statin dose 11.1 17.9 24.1 34.8 60.8 24.2
Moderate risk 78 (33%) 728 (23%) 301 (21%) 124 (25%) 61 (24%) 123 (33%)
Mean statin dose 13.3 17.8 23.1 34.8 61.3 24.3
Low risk 61 (26%) 910 (28%) 428 (30%) 155 (31%) 71 (28%) 107 (28%)
Mean statin dose 10.7 16.9 23.8 33.9 63.9 24.7
Baseline lipids, mean ± SD
LDL-C 143.5 (47.0) 124.4 (43.5)* 118.9 (39.7)* 127.8 (39.7)* 126.8 (35.6)* 139.3 (38.6)
Total cholesterol 217.8 (47.9) 202.0 (44.6)* 195.5 (41.6)* 204.1 (39.4)* 206.8 (42.2)* 220.5 (40.6)
HDL-C 52.1 (14.9) 52.8 (13.9) 52.8 (14.4) 52.7 (13.9) 53.3 (15.1) 55.0 (14.3)
Triglycerides 148.1 (79.6) 144.8 (75.6) 140.1 (75.5) 138.9 (67.3) 146.9 (74.9) 145.3 (79.4)
Statin therapy, mean (SD)
Initial daily dose 12.2 (7.2) 17.5 (12.9) 23.5 (11.5) 34.5 (14.7) 62.0 (24.8) 24.4 (11.0)
Therapy duration§, days 199.5 (123.0) 265.8 (160.4)* 266.1 (161.0)* 263.5 (158.6)* 287.0 (165.3)* 251.1 (158.9)*
< 65 years of age patients (n ¼ 5326)
Number of subjects 353 (6%) 3340 (63%) 944 (18%) 322 (6%) 143 (3%) 224 (4%)
Age (mean ± SD) 53.9 (7.7) 53.8 (7.9) 54.9 (7.4)* 54.9 (7.3) 55.0 (7.6) 55.2 (7.2)*
Male (%) 46 52 52 50 50 47
Smoker (%) 9 10 9 12 12 9
Hypertension (%) 42 37 40 39 36 46
CHD (%) 9 9 8 9 6 9
NCEP risk group, n (%)
CHD/CHD risk equivalent 78 (22%) 969 (29%) 264 (28%) 91 (28%) 31 (22%) 45 (20%)
Mean statin dose 10.5 19.6 24.9 31.8 51.4 24.1
Moderate risks 123 (35%) 735 (22%) 208 (22%) 77 (24%) 36 (25%) 67 (30%)
Mean statin dose 11.9 17.2 24.5 37.5 65.3 23.0
Low risk 152 (43%) 1636 (49%) 472 (50%) 154 (48%) 76 (53%) 112 (50%)
Mean statin dose 10.6 16.2 24.3 33.6 74.4 24.0
Baseline lipids, mean ± SD
LDL-C 163.5 (48.1) 142.2 (46.4)* 140.3 (46.2)* 142.2 (38.4)* 147.9 (37.5)* 153.8 (40.6)*
Total cholesterol 239.8 (43.7) 219.1 (46.1)* 216.6 (44.7)* 218.4 (36.9)* 226.9 (32.2)* 230.5 (41.8)*
HDL-C 48.8 (12.7) 50.1 (13.0) 51.4 (13.5) 50.3 (12.5) 53.3 (13.5) 51.0 (14.6)
Triglycerides 179.6 (99.5) 160.2 (89.2) 156.5 (86.0) 155.8 (80.1) 145.7 (75.7) 157.3 (81.9)
Statin therapy, mean ± SD
Daily dose 11.3 ± 5.3 16.5 ± 12.0 24.3 ± 11.3 35.7 ± 15.0 66.4 ± 21.7 23.5 ± 11.7
Therapy duration§, days 196.7 (121.0) 264.5 (159.4)* 266.0 (158.2)* 288.5 (159.6)* 276.0 (158.8)* 248.9 (153.1)*
*p < 0.05 for comparison with rosuvastatin; CHD risk ¼ high risk + moderate risk with baseline LDL-C < 130 mg/dl; Number of subjects for total cholesterol,
HDL-C and triglycerides were slightly less than that of LDL-C; Medicare-eligible, n ¼ 207 for RSV, 2714 for ATV, 1201 for SMV, 452 for PRV, 219 for FLV and 350
for LOV; < 65 years of age, n ¼ 303 for RSV, 2873 for ATV, 853 for SMV, 298 for PRV, 135 for FLV and 215 for LOV; §Therapy duration was shorter for RSV
because of its more recent commercial availability compared with other statins.
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to be clinically meaningful (17,18). A greater than
6% difference in LDL-C reduction between RSV and
other statins as observed in the present study indi-
cated clinical meaningfulness of the study ﬁndings. A
deﬁnition for clinically meaningful difference in
LDL-C goal attainment has not been established, so
clinicians and payers may need to deﬁne their own
clinically signiﬁcant threshold. However, one could
hypothesise that the clinically and statistically
Table 2 Observed changes in LDL-C levels for Medicare-eligible patients and < 65 years of age patients newly initiated on statin therapy
LDL-C Rosuvastatin Atorvastatin Simvastatin Pravastatin Fluvastatin Lovastatin
< 65 years of age patients
Number of subjects 353 3340 944 322 143 224
Baseline (mg/dl) 163.5 ± 48.1 142.2 ± 46.4* 140.3 ± 46.2* 142.2 ± 38.4* 147.9 ± 37.5* 153.8 ± 40.6*
Follow-up (mg/dl) 102.3 ± 36.6 102.1 ± 31.2 106.7 ± 31.4* 113.6 ± 27.6* 109.4 ± 27.1* 118.8 ± 31.5*
Per cent change (%) 33.6 ± 27.9 22.5 ± 29.4* 19.0 ± 25.6* 17.0 ± 20.2* 23.6 ± 20.1* 20.2 ± 19.9*
Adjusted per cent change (%) 28.5 ± 15.7 21.3 ± 15.7* 18.4 ± 15.7* 15.8 ± 15.7* 20.6 ± 15.7* 14.4 ± 15.7*
Medicare-eligible patients
Number of subjects 235 3195 1432 495 256 376
Baseline (mg/dl) 143.5 ± 47.0 124.4 ± 43.5* 118.9 ± 39.7* 127.8 ± 39.7* 126.8 ± 35.6* 139.3 ± 38.6
Follow-up (mg/dl) 93.8 ± 32.3 95.4 ± 28.6 97.4 ± 29.3 107.3 ± 32.8* 108.0 ± 30.5* 107.9 ± 27.3*
Per cent change (%) 29.8 ± 26.6 17.2 ± 28.8* 12.3 ± 33.0* 12.5 ± 23.7* 11.3 ± 25.1* 19.1 ± 22.0*
Adjusted per cent change (%) 24.3 ± 16.6 17.5 ± 16.6* 14.8 ± 16.6* 11.3 ± 16.6* 10.7 ± 16.6* 13.3 ± 16.6*
*p < 0.05 for comparison of rosuvastatin vs. each other statin; Adjusted for age, gender, smoking, hypertension, CHD, systolic blood pressure, therapy duration
and baseline LDL-C.
Table 3 Per cent change in total cholesterol, HDL-C and triglycerides for Medicare-eligible patients and < 65 years of age patients newly initiated
on statin therapy
Lipid change Rosuvastatin Atorvastatin Simvastatin Pravastatin Fluvastatin Lovastatin
< 65 years of age patients
Total cholesterol
Number of patients 303 2873 853 298 135 215
Per cent total cholesterol change )23.6 (19.9) )17.0 (18.2)* )13.6 (16.7)* )12.0 (13.3)* )16.3 (13.6)* )15.0 (13.7)*
Per cent total cholesterol change adjusted )22.1 (13.9) )17.2 (13.9) )14.1 (13.9)* )10.8 (13.9)* )16.0 (13.9)* )13.6 (13.9)*
HDL-C
Number of patients 303 2770 822 292 134 203
Per cent HDL-C change 1.7 (15.8) 0.8 (14.5) 1.2 (14.2) )0.7 (13.8)* 0.6 (13.2) )1.3 (11.9)*
Triglyceride
Number of patients 301 2764 821 294 135 205
Per cent triglyceride change )2.9 (62.5) )4.5 (45.5) )2.6 (39.3) 2.8 (40.2) )2.1 (33.7) )4.8 (30.8)
Medicare-eligible patients
Total cholesterol
Number of patients 207 2714 1201 452 219 350
Per cent total cholesterol change )19.3 (18.6) )12.3 (18.6)* )8.9 (17.2)* )9.3 (14.1)* )7.9 (16.4)* )13.2 (14.8)*
Per cent total cholesterol change adjusted )17.5 (10.6) )12.2 (10.6)* )10.7 (10.6)* )8.8 (10.6)* )7.0 (10.6)* )8.8 (10.6)*
HDL-C
Number of patients 206 2696 1203 450 217 347
Per cent HDL-C change 3.4 (14.6) 1.2 (15.0)* 1.7 (14.6) 1.6 (18.8) 1.8 (15.3) 0.8 (13.0)*
Triglyceride
Number of patients 204 2698 1202 450 219 346
Per cent triglyceride change 15.7 (142.3) 2.0 (64.2) 9.8 (100.2) 5.4 (61.2) 5.0 (50.5) 4.9 (65.2)
*p < 0.05 for comparison of rosuvastatin vs. each other statin; Adjusted for age, gender, smoking, hypertension, CHD, systolic blood pressure, therapy duration
and baseline LDL-C.
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observed in this study should equate to a clinically
meaningful difference in goal attainment.
The present study only focused on lipid changes
and goal attainment comparisons of RSV with other
statins and did not examine mortality or cardiovas-
cular event differences as end-points. Clinical trials
examining the impact of RSV on mortality and car-
diovascular event outcomes are ongoing (19–21). A
meta analysis of 14 randomised trials of statin ther-
apy indicated that statins safely reduced the 5-year
incidence of major coronary events, coronary revas-
cularisation and stroke by about one-ﬁfth per mmol/
l (39 mg/dl) reduction in LDL-C (22). This analysis
found an approximately linear relationship between
the absolute reductions in LDL-C achieved and the
proportional reductions in the incidence of coronary
and other major vascular events and that larger LDL-
C reductions produced larger reductions in vascular
disease risk. These results cannot be directly applied
to the current study ﬁndings as it is not a rando-
mised trial and there are obvious differences in
inclusion criteria and follow-up period between the
trials included in the meta analysis when compared
with the current observational study. However, one
can use the results of the meta analysis to arrive at a
general guidance of the expected beneﬁts in terms of
avoided cardiovascular events. Extrapolating to the
study’s 49.7 mg/dl average absolute reduction in
LDL-C for Medicare-eligible patients and 61.2 mg/dl
average absolute reduction in LDL-C for < 65 years
of age patients with RSV, it could be estimated that
continued RSV therapy could reduce major vascular
events by one-fourth and one-third respectively. Such
estimates can also be projected for other statins in
this study or for differences in LDL-C reduction
observed between different statins.
This study provides evidence of greater effectiveness
of RSV in usual care. The data reﬂect patients treated
in the community, largely by primary care physicians,
and represent clinicians’ treatment patterns for their
statin patients. Moreover, this is the ﬁrst investigation
to provide effectiveness estimates of statins for the
Medicare-eligible population. Other studies have
derived estimates from clinical trial populations and
managed care populations which tend to be predomi-
nantly younger and employed rather than ‡ 65 and
retired. It is also important to recognise that many
patients on statin therapy (both Medicare-eligible and
< 65 years) were not achieving their LDL-C goal in
usual care. As few as 51–65% of patients reached goal
on LOV, PRV or FLV, leaving 34–49% of patients not
attaining LDL-C goal. Thus, the selection of a statin
that increases the likelihood of attaining goal is impor-
tant. Future studies need to examine speciﬁc reasons
for this low LDL-C goal attainment rate and limited
adoption of guidelines.
Statin therapy utilisation patterns were different
between patients with ‡ 65 and < 65 years of age,
with more Medicare-eligible patients receiving
Table 4 ATP III LDL-C goal attainment for rosuvastatin vs. other statins for Medicare-eligible patients and < 65 years of age patients by CHD
risk group
Statin therapy
< 65 years of age Medicare-eligible
Number of
subjects
Unadjusted percentage
attaining LDL-C goal
Adjusted percentage
attaining LDL-C goal
Number of
subjects
Unadjusted percentage
attaining LDL-C goal
Adjusted percentage
attaining LDL-C goal
Moderate- and high-CHD risk
Rosuvastatin 187 73.6 (44.2) 78.4 (8.6) 136 74.1 (43.9) 76.0 (7.1)
Atorvastatin 1407 70.4 (45.6) 71.5 (9.4)* 1526 70.2 (45.7) 73.0 (7.5)*
Simvastatin 381 66.3 (47.3) 66.9 (10.3)* 623 62.0 (48.6)* 64.1 (8.6)*
Pravastatin 133 55.6 (49.8)* 59.7 (11.5)* 228 57.6 (49.5)* 59.5 (8.9)*
Fluvastatin 57 63.2 (48.6) 65.8 (10.9)* 118 48.6 (50.2)* 50.5 (9.0)*
Lovastatin 109 55.0 (50.0)* 51.3 (11.5)* 213 62.4 (48.5)* 64.8 (8.5)*
Low CHD risk
Rosuvastatin 90 90.0 (30.2) 91.0 (7.7) 24 89.5 (31.5) 85.4 (11.0)
Atorvastatin 713 90.2 (29.7) 91.0 (7.6) 205 91.3 (28.3) 85.7 (10.9)
Simvastatin 179 89.5 (30.7) 90.1 (7.7) 72 90.0 (30.2) 83.0 (12.1)
Pravastatin 58 83.6 (37.3) 82.6 (12.0)* 27 82.8 (38.4) 74.7 (14.9)*
Fluvastatin 28 92.6 (26.7) 91.0 (7.1) 8 81.8 (40.4) 72.2 (15.5)
Lovastatin 54 80.4 (40.1)* 82.5 (12.0)* 41 94.3 (23.5) 88.8 (9.2)
*p < 0.05 for comparison of rosuvastatin vs. each other statin; Adjusted for per cent LDL-C reduction needed to reach goal, age, gender, smoking, hypertension,
CHD, systolic blood pressure and therapy duration.
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(28%). Additionally, age ‡ 65 was an independent
predictor of LDL-C outcomes in the total popula-
tion. Hence, we examined statin effectiveness in the
age-stratiﬁed groups of < 65 and ‡ 65.
Our effectiveness estimates were generally lower
than (11–28% LDL-C reduction) other investigations
in the real-world setting (4,16,23,24). This may be
because our database included prescription order data
rather than pharmacy dispensing data. Assuming that
this potential bias may have impacted the effective-
ness estimates of all statins (i.e. no documented evi-
dence of differences across statins), the relative
differences in the effectiveness of one statin compared
with the other would remain unchanged. Moreover,
our LDL-C estimates represent usual care, reﬂecting
what physicians may observe with their patients,
including the impact of compliance with therapy, diet
and exercise on overall therapy effectiveness. A recent
investigation examined the effectiveness of RSV vs.
ATV in usual care setting and found greater LDL-C
reduction (34% vs. 27%) and goal attainment (odds
ratio ¼ 1.9) in RSV patients compared with ATV
(25). This study did not examine statin effectiveness
in the Medicare-eligible patients and < 65 years of
age patients and did not evaluate all statins as has
been done in the present study. Difference in the
magnitude of effectiveness between the two studies
may be related to differences in the nature of data
sources (EMR vs. claims databases) and populations.
Likewise, the Bullano 2006 study compared RSV
effectiveness with all other statins and found RSV was
more effective in reducing LDL-C and attaining LDL-
C goals in a usual care setting (16). The present study
conﬁrms these ﬁndings using a prescription (as
opposed to dispensing) type of dataset and in deﬁned
subpopulations of patients (deﬁned by age categories
of < 65 and ‡ 65 years) in usual care. The differences
in study populations and data source between the
present study and previous studies further highlight
the uniqueness of the present study and, importance
and relevance of the present study results in patient
care decisions.
Differences between clinical trial efﬁcacy and real-
world effectiveness of statins has been previously
reported (23). The purpose of the present investiga-
tion was to determine if the greater LDL-C lowering
efﬁcacy of RSV shown in clinical trials (18) held true
for effectiveness in usual clinical practice as well. Our
ﬁndings conﬁrm previous reports of reduced effec-
tiveness of statins in usual care (as opposed to efﬁ-
cacy observed in clinical trials) across all statins and
also conﬁrm greater LDL-C lowering effectiveness of
RSV when compared with other statins in usual clin-
ical practice.
Recent generic availability of SMV has provided
further opportunities to achieve efﬁciency in manage-
ment of patients with dyslipidaemia. To realise efﬁ-
ciencies without compromising quality of care,
appropriate patient-speciﬁc selection for generic sta-
tins and branded statins is required. Our analysis of
real-world clinical practice data indicated that high-
and moderate-risk RSV patients were more likely to
attain LDL-C goals when compared with other statins
(including generic statins). However, no difference in
goal attainment rate between RSV and SMV was
observed in low-risk patients. This suggests that gen-
eric SMV may be used in low-risk patients and RSV
may be used in high- and moderate-risk patients to
achieve effective and efﬁcient management of dyslip-
idaemia in the population. An extensive and formal
cost-effectiveness evaluation of statins was beyond the
scope of this study. However, using the observed
effectiveness from this study and the wholesale acqui-
sition costs for statin therapy (First DataBank
National Drug Data File), a cost-effectiveness ratio
(cost per LDL-C reduction) for RSV would be $3359
for patients < 65 years of age and $3683 for Medi-
care-eligible patients and $5251 and $6969 for ATV
patients < 65 years of age and Medicare-eligible
respectively. For generic SMV, a rough cost-effective-
ness ratio would be between $373 and $458 for
patients < 65 years of age and between $584 and
$716 for Medicare-eligible patients when using $0.06–
$0.10 (26) for generic SMV tablet. These cost-effec-
tiveness data further demonstrate that RSV may be
used as the branded statin for effective and efﬁcient
management of dyslipidaemia among patients requir-
ing a large reduction in LDL-C and generic SMV may
be the efﬁcient and appropriate generic statin for
patients requiring a smaller LDL-C reduction.
Our study has limitations that should be consid-
ered. The study population includes patients treated
by physicians utilising an electronic medical record
system in their clinical practice. Although over 3000
physicians across the US are included, there may be
differences in clinical practice patterns between phy-
sicians who utilise GEMS and physicians who are
not electronically equipped. However, our study pop-
ulation included a more heterogeneous group of
patients with Medicare health insurance and those
with Medigap and/or commercial insurance rather
than investigations that focussed only on employed
patient populations in managed care (4,19,20). Selec-
tion bias may have occurred because of the observa-
tional nature of the study. Yet, multivariate analyses
were employed to control for differences in demo-
graphics and clinical characteristics. Moreover, the
study pharmacy data is the physician prescription
order and not pharmacy claims data. Therefore, it
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tion orders were ﬁlled by the patient. To reduce
introduction of potential bias because of non-ﬁlling
of some prescriptions, only those patients with at
least 90 days supply of statin therapy were included.
An additional limitation is the lack of inpatient pro-
cedure data in the GEMS database. Patients with
angioplasty, coronary artery bypass graft and other
revascularisation procedures are classiﬁed as high-risk
patients according to NCEP ATP III (2). These
patients could not be distinguished in our dataset
thereby reducing the size and composition of our
high-risk group. Furthermore, diagnoses from spe-
cialists (e.g. cardiologists) were under-represented in
our data as the majority of physicians were primary
care clinicians. Cardiovascular events could not be
ascertained completely in our dataset, so the impact
of different statins on the incidence of cardiovascular
events could not be assessed. Longer follow-up stud-
ies with availability of both inpatient and outpatient
data are needed to address the potential differential
impact of statins on cardiovascular events.
Conclusions
The study results indicated that RSV is more effec-
tive in lowering LDL-C and total cholesterol among
elderly and non-elderly patients than other statins.
RSV is also more effective in attaining LDL-C goal
among high- and moderate-risk patients for both
elderly and non-elderly patients than other statins.
For low-risk patients, in general there were no sub-
stantial differences in LDL-C goal attainment across
statins (in particular between RSV vs. ATV, SMV
and FLV). Rosuvastatin effectiveness (LDL-C reduc-
tion and goal attainment) has implications for phy-
sicians in selecting the optimal statin agent to meet
their individual patient needs in both the Medi-
care-eligible patients and patients < 65 years of age.
For both Medicare-eligible patients and < 65 years
of age patients, RSV may be used in moderate-
and high-risk patients and generic statins may be
used in low-risk patients to achieve effective and
efﬁcient management of dyslipidaemia. These ﬁnd-
ings provide physicians and healthcare plans with a
better understanding of the differential effectiveness
of statin therapy for patient care and formulary
management.
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